MASLD vs. MASH vs. Fibrosis: What the Terms Mean

MASLD, MASH, and fibrosis describe related but distinct points along the same disease process. MASLD is the umbrella term for fat buildup in the liver. MASH is a more serious subtype where that fat has triggered inflammation. Fibrosis is the scarring that can develop as a result. Not everyone with MASLD progresses to the later stages.

What Is MASLD?

MASLD, metabolic dysfunction-associated steatotic liver disease, is diagnosed when excess fat accumulates in the liver alongside at least one cardiometabolic risk factor, such as obesity, type 2 diabetes, or high blood pressure. We cover the basics of MASLD in more depth here. At this stage, the liver may show fat but no significant inflammation or damage yet.

What Makes MASH Different?

MASH, metabolic dysfunction-associated steatohepatitis, is the more advanced, inflamed form of the same underlying condition. The distinction matters because inflammation is what drives the risk of lasting damage. Simple fat buildup alone doesn’t reliably predict future liver problems the way active inflammation does.

Practice guidance from the American Association for the Study of Liver Diseases treats MASH as a distinct, more clinically significant diagnosis within the broader MASLD spectrum, not simply a worse version of the same number.

Where Does Fibrosis Fit In?

Fibrosis is scar tissue that can form as a consequence of ongoing inflammation. It’s staged on a scale, with higher stages indicating more extensive scarring. Fibrosis can develop in people with MASH, and its presence and severity are what most influence long-term outlook, more so than the amount of fat alone.

In simple terms, the progression usually looks like this:

• Fat accumulates (MASLD, simple steatosis)
• Inflammation develops (MASH)
• Scar tissue forms in response to that inflammation (fibrosis)
• Extensive scarring impairs liver function (cirrhosis)

Can You Have MASLD Without MASH?

Yes, and most people do. Simple steatosis, fat without significant inflammation, is the more common presentation, and it doesn’t automatically progress to MASH or fibrosis. This is part of why MASLD alone isn’t considered as urgent a diagnosis as MASH, even though both fall under the same broader term.

How Do Doctors Tell These Apart?

A liver biopsy remains the definitive way to confirm MASH, since it directly examines inflammation and cell damage under a microscope, something imaging alone can’t fully replicate. Noninvasive tools like point-of-care ultrasound elastography can estimate liver stiffness and fat content and flag when fibrosis risk appears elevated, which helps guide whether more invasive testing or closer monitoring makes sense.

At MacArthur Gastroenterology, that noninvasive first step is done using our advanced liver scan, which measures stiffness and fat content in a single office visit.

If you’re unsure where you stand on this spectrum, our fatty liver screening page is a reasonable place to start.

Frequently Asked Questions

Is MASH just a more severe version of MASLD?

MASH is a distinct diagnosis within the MASLD spectrum, defined by active inflammation rather than fat alone. Not everyone with MASLD develops MASH.

Can fibrosis be present without MASH?

Fibrosis typically develops as a consequence of the inflammation seen in MASH, though the pace and pattern can vary between individuals.

Does a noninvasive scan replace a liver biopsy?

Not for a definitive MASH diagnosis. Noninvasive scans estimate stiffness and fat and help guide next steps, but a biopsy remains the most direct way to confirm inflammation.

Is this article a substitute for medical advice?

No. This content is educational and general in nature, not medical advice. Talk with your physician about what your specific results mean.

References

• AASLD Practice Guidance on NAFLD, Hepatology 2023, via PubMed
• NIDDK, Definition & Facts of NAFLD & NASH